Stefano Sammicheli

Company: Ichnos Sciences

Job title: Director, Innate Cell Engagers

Seminars:

ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38 Positive Hematologic Malignancies 3:15 pm

ISB 1442 represents a novel approach for the treatment of CD38+ tumors by cotargeting CD38 and CD47 with a 2+1 biparatopic bispecific antibody format with Fc engineering enhancing Fc effector functions ISB 1442 shows higher potency relative to daratumumab in CD38high/low tumor models as measured by multiple antibody-dependent mechanisms of action in vitro and in…Read more

day: Day One